Literature DB >> 22954612

Travel medicine and vaccines for HIV-infected travelers.

D Scott Smith1.   

Abstract

For the purposes of vaccination, persons with asymptomatic HIV infection and CD4+ cell counts of 200/μL to 500/μL are considered to have limited immune deficits and are generally candidates for immunization. HIVinfected persons with CD4+ cell counts less than 200/μL or history of an AIDS-defining illness should not receive live-attenuated viral or bacterial vaccines because of the risk of serious systemic disease and suboptimal response to vaccination. Available data indicate that immunization during antiretroviral therapy restores vaccine immunogenicity, improves the rate and persistence of immune responses, and reduces risk of vaccine-related adverse events, although vaccine responses often are suboptimal. Major issues for travelers to the developing world are vaccine-preventable illnesses (hepatitis A virus, yellow fever, and typhoid fever), traveler's diarrhea, and malaria. This article summarizes a presentation by D. Scott Smith, MD, at the IAS-USA continuing medical education program held in San Francisco in April 2012.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22954612      PMCID: PMC6148944     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  4 in total

1.  Response to hepatitis A vaccine in HIV-positive patients.

Authors:  S Weissman; C Feucht; B A Moore
Journal:  J Viral Hepat       Date:  2006-02       Impact factor: 3.728

2.  Putting typhoid vaccination on the global health agenda.

Authors:  Denise DeRoeck; Luis Jodar; John Clemens
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

3.  Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients.

Authors:  Jérôme Pacanowski; Karine Lacombe; Pauline Campa; Magdalena Dabrowska; Jean-Dominique Poveda; Jean-Luc Meynard; Jean-Louis Poirot; Laurent Fonquernie; Pierre-Marie Girard
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

4.  Spectrum of disease and relation to place of exposure among ill returned travelers.

Authors:  David O Freedman; Leisa H Weld; Phyllis E Kozarsky; Tamara Fisk; Rachel Robins; Frank von Sonnenburg; Jay S Keystone; Prativa Pandey; Martin S Cetron
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

  4 in total
  2 in total

Review 1.  Prospects for dengue vaccines for travelers.

Authors:  Sl-Ki Lim; Yong Seok Lee; Suk Namkung; Jacqueline K Lim; In-Kyu Yoon
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

Review 2.  Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.

Authors:  Nancy F Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2017-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.